Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$0.26 - $0.61 $8,731 - $20,485
33,582 New
33,582 $9,000
Q1 2023

May 15, 2023

BUY
$0.18 - $0.57 $5,485 - $17,370
30,475 New
30,475 $9,000
Q3 2022

Nov 14, 2022

BUY
$0.05 - $10.7 $1,597 - $341,811
31,945 New
31,945 $11,000

Others Institutions Holding PHGE

About BiomX Inc.


  • Ticker PHGE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,982,300
  • Market Cap $19.2M
  • Description
  • BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibr...
More about PHGE
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.